There have been major advances in the armamentarium for hepatocellular carcinoma (HCC) since the last official update of the Barcelona Clinic Liver Cancer prognosis and treatment strategy published in 2018. Whilst there have been advances in all areas, we will focus on those that have led to a change in strategy and we will discuss why, despite being encouraging, data for select interventions are still too immature for them to be incorporated into an evidence-based model for clinicians and researchers. Finally, we describe the critical insight and expert knowledge that are required to make clinical decisions for individual patients, considering all of the parameters that must be considered to deliver personalised clinical management.

自 2018 年巴塞罗那诊所肝癌预后和治疗策略最新官方更新发布以来，肝细胞癌 (HCC) 的治疗取得了重大进展。虽然所有领域都取得了进展，但我们将重点关注那些领先的领域我们将讨论为什么尽管令人鼓舞，但特定干预措施的数据仍然太不成熟，无法纳入临床医生和研究人员的循证模型中。最后，我们描述了为个体患者做出临床决策所需的关键洞察力和专业知识，考虑了提供个性化临床管理必须考虑的所有参数。